Apogee Therapeutics (APGE) Earnings Analysis

Apogee Therapeutics (APGE) next reports earnings on 2026-08-10, consensus EPS -1.1 USD. Last quarter (2026-05-11) it beat with EPS -1.06 USD vs -1.07 USD est (+0.9%). It has beaten estimates in 5/7 recent quarters (71%). Trailing P/E -30.97.

Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades

When does APGE next report earnings?

Next earnings date2026-08-10
Consensus EPS estimate-1.1 USD
Revenue estimate0.01B

APGE earnings history — beats and misses

Quarter (report date)EPS actualEPS est.SurpriseResult
2026-05-11-1.06 USD-1.07 USD+0.9%Beat
2026-03-02-1.03 USD-1.05 USD+1.9%Beat
2025-11-10-1.11 USD-1.12 USD+0.9%Beat
2025-08-11-1.13 USD-1.03 USD-9.7%Miss
2025-05-12-0.95 USD-1.19 USD+20.2%Beat
2025-03-03-1.19 USD-0.94 USD-26.6%Miss
2024-08-12-0.6 USD-0.64 USD+6.3%Beat

Beat rate: 5/7 (71%) over reported quarters with consensus data.

APGE valuation and analyst view

Trailing P/E-30.97
Trailing EPS-3.94174 USD
Price / book7.44
Dividend yield0.00%
Market cap8.30B
Analyst consensusHold (3 buy / 11 hold / 0 sell)
Avg price target122.93 USD

Related research pages

Frequently asked questions

When is Apogee Therapeutics (APGE)'s next earnings date?

Apogee Therapeutics is next scheduled to report on 2026-08-10, with a consensus EPS estimate of -1.1 USD and revenue estimate of 0.01B.

Did APGE beat earnings last quarter?

In its 2026-05-11 report, APGE posted EPS of -1.06 USD versus a -1.07 USD estimate — a beat of 0.9%.

What is APGE's earnings track record?

Over the last 7 reported quarters with consensus data, APGE beat estimates 5 times (71%).

What is APGE's current P/E ratio and EPS?

APGE trades at a trailing P/E of -30.97 on trailing EPS of -3.941741826596689 USD.

What do analysts rate APGE?

Analyst consensus is "Hold" across 14 ratings (0 strong buy, 3 buy, 11 hold, 0 sell, 0 strong sell). Average 12-month price target: 122.93 USD.